AstraZeneca’s diabetes drug, Onglyza (saxagliptin), showed an increased risk of death in an analysis conducted by FDA. FDA asked all manufactures to provide evidence that type 2 diabetes products do not increase the risk of heart failure since 2008. FDA staff said the used of Onglyza increases the risk of death from all causes, no just from heart failure. However, the analysts did not find the cause of the increased risk. Another trial from Merck’s Januvia is complete and expected to publish in the American Diabetes Association in June. Until then, the increase risk of death by DDP-4 inhibitors is inconclusive to determine by the advisory panel. What is your experience with DDP-4 inhibitors? What are your thoughts about FDA’s findings?
For more information, please see Bloomberg.
Image courtesy of [Stuart Miles]/http://www.freedigitalphotos.net